LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | PI103 | 10 | uM | LJP6 | 3 | I13 | 72 | hr | 658 | 938 | 3769 | 0.2488 | 0.1511 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 658 | 3095 | 3908 | 0.7919 | 0.8264 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 658 | 3315 | 3953 | 0.8385 | 0.8683 |
Hs 578T | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 658 | 3155 | 3938 | 0.8011 | 0.8353 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 658 | 2070 | 3908 | 0.5296 | 0.5618 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 658 | 2369 | 3953 | 0.5992 | 0.6407 |
Hs 578T | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 658 | 2229 | 3938 | 0.5660 | 0.6042 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 658 | 1051 | 3908 | 0.2689 | 0.1997 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 658 | 1127 | 3953 | 0.2851 | 0.2311 |
Hs 578T | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 658 | 1133 | 3938 | 0.2877 | 0.2342 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 658 | 1001 | 3908 | 0.2561 | 0.1772 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 658 | 1015 | 3953 | 0.2567 | 0.1823 |
Hs 578T | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 658 | 1071 | 3938 | 0.2719 | 0.2076 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 658 | 1138 | 3908 | 0.2912 | 0.2374 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 658 | 1227 | 3953 | 0.3103 | 0.2723 |
Hs 578T | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 658 | 1248 | 3938 | 0.3169 | 0.2813 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 658 | 825 | 3908 | 0.2111 | 0.0919 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 658 | 874 | 3953 | 0.2211 | 0.1159 |
Hs 578T | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 658 | 907 | 3938 | 0.2303 | 0.1323 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 658 | 3250 | 3908 | 0.8315 | 0.8615 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 658 | 3502 | 3953 | 0.8858 | 0.9084 |
Hs 578T | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 658 | 3521 | 3938 | 0.8940 | 0.9150 |
Hs 578T | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 658 | 3309 | 3908 | 0.8466 | 0.8745 |
Hs 578T | GSK 690693 | 0.12 | uM | LJP5 | 2 | F23 | 72 | hr | 658 | 3354 | 3953 | 0.8483 | 0.8768 |
Hs 578T | GSK 690693 | 0.12 | uM | LJP5 | 3 | F23 | 72 | hr | 658 | 3408 | 3938 | 0.8653 | 0.8910 |